HDTRA124C0008

GENERATION OF A NOVEL ANTIBODY-ANTIBIOTIC CONJUGATE AS A COMBINATION THERAPY PLATFORM TO TREAT MELIOIDOSIS OR PLAGUE.

Research the contractor View USAspending source Save to my pursuit research

Award details

Obligations, current value and potential value describe different measures; they are never added together.

Field	Reported value
Agency	Department of Defense
Office	DEFENSE THREAT REDUCTION AGENCY
NAICS	541714 — Research and Development in Biotechnology (except Nanobiotechnology)
PSC	AC32 — NATIONAL DEFENSE R&D SERVICES; DEFENSE-RELATED ACTIVITIES; APPLIED RESEARCH
Parent award / vehicle	Not reported
Set-aside	NO SET ASIDE USED.
Pricing type	COST PLUS FIXED FEE
Obligations	$5.6M
Current contract value	$5.6M
Potential contract value / ceiling	$8.4M
Start date	Jun 10, 2024
Current end date	Jun 9, 2027
Potential end date	Dec 9, 2029
Latest award activity	May 18, 2026
Source loaded	Sep 26, 2026

Funding and modification history

Showing the latest 10 of 10 loaded transactions. Negative values are deobligations.

Date	Modification	Obligation change	Description
May 18, 2026	P00008	$2.0M	THRUST 7 - GENERATION OF A NOVEL ANTIBODY - ANTIBIOTIC CONJUGATE AS A COMBINATION THERAPY PLATFORM TO TREAT MELIODOSIS
Jan 7, 2026	P00007	$1.5M	THRUST 7 - GENERATION OF A NOVEL ANTIBODY - ANTIBIOTIC CONJUGATE AS A COMBINATION THERAPY PLATFORM TO TREAT MELIODOSIS
Aug 26, 2025	P00006	$0	THRUST 7 - GENERATION OF A NOVEL ANTIBODY - ANTIBIOTIC CONJUGATE AS A COMBINATION THERAPY PLATFORM TO TREAT MELIODOSIS
Jul 30, 2025	P00005	$778.7K	THRUST 7 - GENERATION OF A NOVEL ANTIBODY - ANTIBIOTIC CONJUGATE AS A COMBINATION THERAPY PLATFORM TO TREAT MELIODOSIS
Jun 11, 2025	P00004	$221.3K	THRUST 7 - GENERATION OF A NOVEL ANTIBODY - ANTIBIOTIC CONJUGATE AS A COMBINATION THERAPY PLATFORM TO TREAT MELIODOSIS
May 16, 2025	P00003	$0	THRUST 7 - GENERATION OF A NOVEL ANTIBODY - ANTIBIOTIC CONJUGATE AS A COMBINATION THERAPY PLATFORM TO TREAT MELIODOSIS
Mar 6, 2025	P00002	$186.3K	PHARMACOLOGICAL AND BIOLOGIC INTERVENTION TO REDUCE INFLAMMATION AND SEIZURES CAUSED BY ENCEPHALITIS
Feb 19, 2025	P00001	$385.7K	PHARMACOLOGICAL AND BIOLOGIC INTERVENTION TO REDUCE INFLAMMATION AND SEIZURES CAUSED BY ENCEPHALITIS
Oct 30, 2024	A00001	$0	UNDEFINITIZED ORDER THURST 7 -GENERATION OF NOVEL ANTIBODY - ANTIBIOTIC CONJUGATE AS A COMBINATION THERAPY PLATFORM TO TREAT MELIODOSIS
Jun 6, 2024	0	$534.6K	GENERATION OF A NOVEL ANTIBODY-ANTIBIOTIC CONJUGATE AS A COMBINATION THERAPY PLATFORM TO TREAT MELIOIDOSIS OR PLAGUE.

Estimated positioning window

Dec 9, 2028 – Jun 9, 2029

Recompete signal:

35/100

Why this recompete signal

Contract timing and recorded acquisition signals at the time of calculation.

Stored score: 35/100. Available recorded signals: 30 points.

Contract end 2029-12-09 (1141 days from calculation): +5 points
1 historical awards in this buyer and category group: +0 points
10 recorded award transactions: +10 points
Latest award action: 2026-05-18: +5 points
Parent award identifier recorded: +0 points
Solicitation identifier recorded: +10 points
Linked official forecast: +0 points
Calculated on: 2026-10-25 10:18:04.631876+00:00

The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.

Rule-based research score; it does not measure your chance of winning.

This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.

USAspending award record

. Rule-based research score; positioning dates are estimates.

Recompete score calculated Oct 25, 2026.

Research next steps

Check the linked forecast or SAM for a confirmed solicitation and current timing.
Verify whether remaining options may extend performance beyond the current end date.
Check the stated set-aside against the solicitation and current certifications.
Review the award scope and buyer evidence before making a bid/no-bid decision.